Literature DB >> 23212778

Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma.

Augusto Villanueva1, Josep M Llovet.   

Abstract

Entities:  

Year:  2012        PMID： 23212778     DOI： 10.1002/hep.26124

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  7 in total

1.  Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis.

Authors:  Linda Calistri; Cesare Cordopatri; Cosimo Nardi; Elena Gianni; Fabio Marra; Stefano Colagrande
Journal:  Mol Clin Oncol       Date:  2017-01-16

2.  A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma.

Authors:  Chia-Jui Yen; Tae-You Kim; Yin-Hsun Feng; Yee Chao; Deng-Yn Lin; Baek-Yeol Ryoo; Dennis Chin-Lun Huang; David Schnell; Julia Hocke; Arsène-Bienvenu Loembé; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2018-03-15       Impact factor: 11.740

3.  Genomic Characterization and Comparison of Multi-Regional and Pooled Tumor Biopsy Specimens.

Authors:  Je-Gun Joung; Joon Seol Bae; Sang Cheol Kim; HyunChul Jung; Woong-Yang Park; Sang-Yong Song
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

4.  Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression.

Authors:  Masaaki Kondo; Kazushi Numata; Koji Hara; Akito Nozaki; Hiroyuki Fukuda; Makoto Chuma; Shin Maeda; Katsuaki Tanaka
Journal:  Gastroenterol Res Pract       Date:  2017-06-22       Impact factor: 2.260

5.  Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.

Authors:  Masaaki Kondo; Manabu Morimoto; Satoshi Kobayashi; Shinichi Ohkawa; Hisashi Hidaka; Takahide Nakazawa; Hiroshi Aikata; Takeshi Hatanaka; Daichi Takizawa; Kotaro Matsunaga; Chiaki Okuse; Michihiro Suzuki; Masataka Taguri; Takako Ishibashi; Kazushi Numata; Shin Maeda; Katsuaki Tanaka
Journal:  BMC Cancer       Date:  2019-10-15       Impact factor: 4.430

6.  Prognostic Value of the Preoperative Lymphocyte-C-Reactive Protein Ratio in Hepatocellular Carcinoma Patients Treated with Curative Intent: A Large-Scale Multicentre Study.

Authors:  Yong-Fa Zhang; Liang-He Lu; Chong Zhong; Min-Shan Chen; Rong-Ping Guo; Lu Wang
Journal:  J Inflamm Res       Date:  2021-06-10

7.  Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response.

Authors:  Giuseppe Cabibbo; Marcello Maida; Chiara Genco; Nicola Alessi; Marco Peralta; Giuseppe Butera; Massimo Galia; Giuseppe Brancatelli; Claudio Genova; Maurizio Raineri; Emanuele Orlando; Simona Attardo; Antonino Giarratano; Massimo Midiri; Vito Di Marco; Antonio Craxì; Calogero Cammà
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.